Completed

i-PDTA Pilot Clinical Trial to Reduce Side-Effects of Photodynamic Therapy for the Treatment of Moderate to Severe Acne

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

20 % Aminolevulinic Acid

+ 20 % Aminolevulinic Acid

+ Blue light only

DrugDevice
Who is being recruted

Neurologic Manifestations+6

+ Sebaceous Gland Diseases

+ Signs and Symptoms

From 14 to 50 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1
Interventional
Study Start: November 2009
See protocol details

Summary

Principal SponsorMassachusetts General Hospital
Last updated: February 20, 2025
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2009

Actual date on which the first participant was enrolled.

This is a pilot study to compare efficacy and side effects i-PDT and ALA-PDT. All subjects will receive ALA-PDT and i-PDT. Face or back regions will be divided into two sides, the right and left. One half of the face or back will receive ALA-PDT and the other half will receive i-PDT. For subjects with back acne, red light and blue light alone will be applied for comparison. Healthy subjects with difficult to treat moderate or severe acne on the face or back are eligible to enroll. The investigators will enroll about 35 patients at Massachusetts General Hospital (MGH) with follow-ups 1, 3 and 6 months after treatment.

Principal SponsorMassachusetts General Hospital
Last updated: February 20, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

35 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 14 to 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Neurologic ManifestationsSebaceous Gland DiseasesSigns and SymptomsSkin DiseasesPathological Conditions, Signs and SymptomsSkin and Connective Tissue DiseasesAcneiform EruptionsAcne VulgarisPain

Criteria

Inclusion criteria Subjects with ages between 14 and 50 years, male or female. Subjects with severe acne lesions (one or more nodules or cysts present) on their backs or face Presence of moderate acne on the back and/or face that has been recalcitrant to previous treatments. Recalcitrant acne is acne with no or mild/temporary (less than 3 months) improvement after using: Accutane® for at least one completed treatment cycle, and/or Oral antibiotic for ≥ 3 months; and/or Topical prescription retinoids (tretinoin - retinoic acid, adapalene, tazarotene or other derivatives) for ≥ 3 months, and/or Topical benzoyl peroxide 2.5% or higher concentrations for ≥ 3 months Hormonal treatments** for ≥ 3 months. Willingness to participate in the study Willingness to receive ALA-PDT treatment Informed consent agreement signed by the subject Willingness to follow the treatment schedule and post treatment care requirements Willingness to not use topical or systemic (oral) anti-acne medications including medicated shampoo or soap during the study period. Exclusion criteria Subjects receiving concurrent oral retinoids or antibiotics ** Subjects with chronic use of antibiotics may be included if proven that its use has not changed the severity of their acne. AND *** Chronic use of antibiotic is considered ≥ 2 years of continuous use. Scarring or infection of the area to be treated Known photosensitivity Presence of suntan in the area to be treated Subjects who have taken medication known to induce photosensitivity in the previous 3 months Subjects who have had prior oral retinoid (Accutane®) use within 6 months of entering the study Prior oral antibiotic use within 1 month of entering the study (see exclusion #1) Topical antibiotic or other topical anti-acne treatments use within 2 weeks of entering the study Known anticoagulation or thromboembolic condition Subjects who are immunosuppressed Subject is unable to comply with treatment, home care or follow-up visits Subject is pregnant or breast feeding Subject has a history of being on photosensitive medications (thiazides [used to treat high blood pressure], tetracyclines, fluoroquinolones griseofulvin or sulfonamides [used to treat infections], sulfonylureas [used to treat diabetes], calcium channel blockers [used to treat hypertension]. phenothiazines [used to treat serious emotional problems]). Known skin sensitivity to blue light Porphyria (a disorder of the metabolism that can lead to sensitivity to light) Allergies to chemicals called porphyrins Subjects who started hormonal treatment (for medical conditions or birth control) within less than 3 months.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

5 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

No Intervention
No drug, no treatment

Group II

Active Comparator
Drug- topical 20% Aminolevulinic acid - ALA followed by red light irradiation - conventional photodynamic therapy -PDT

Group III

Experimental
Drug - topical 20% Aminolevulinic acid - followed by inhibitory light during incubation time, then red light for photodynamic therapy

Group IV

Active Comparator
Red light only - no drug

Group 5

Active Comparator
Blue light only - no drug

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers